Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 2
1990 1
1992 1
1993 1
1994 1
1995 1
1996 1
1999 1
2001 1
2004 2
2005 3
2006 2
2007 2
2008 6
2009 2
2010 4
2011 9
2012 4
2013 3
2014 3
2015 4
2016 6
2017 2
2018 8
2019 4
2020 12
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

80 results
Results by year
Filters applied: . Clear all
Page 1
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12.
Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S, Piot C, Engblom C, Pfirschke C, Siwicki M, Gungabeesoon J, Freeman GJ, Warren SE, Ong S, Browning E, Twitty CG, Pierce RH, Le MH, Algazi AP, Daud AI, Pai SI, Zippelius A, Weissleder R, Pittet MJ. Garris CS, et al. Among authors: daud ai. Immunity. 2018 Dec 18;49(6):1148-1161.e7. doi: 10.1016/j.immuni.2018.09.024. Epub 2018 Dec 11. Immunity. 2018. PMID: 30552023 Free PMC article.
Immunotherapy for melanoma.
Cuevas LM, Daud AI. Cuevas LM, et al. Among authors: daud ai. Semin Cutan Med Surg. 2018 Jun;37(2):127-131. doi: 10.12788/j.sder.2018.028. Semin Cutan Med Surg. 2018. PMID: 30040090 Review.
A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments.
Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, Nelson AE, Loo K, Kumar R, Rosenblum MD, Alvarado MD, Wolf DM, Bogunovic D, Bhardwaj N, Daud AI, Ha PK, Ryan WR, Pollack JL, Samad B, Asthana S, Chan V, Krummel MF. Barry KC, et al. Among authors: daud ai. Nat Med. 2018 Aug;24(8):1178-1191. doi: 10.1038/s41591-018-0085-8. Epub 2018 Jun 25. Nat Med. 2018. PMID: 29942093 Free PMC article.
Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity.
Binnewies M, Mujal AM, Pollack JL, Combes AJ, Hardison EA, Barry KC, Tsui J, Ruhland MK, Kersten K, Abushawish MA, Spasic M, Giurintano JP, Chan V, Daud AI, Ha P, Ye CJ, Roberts EW, Krummel MF. Binnewies M, et al. Among authors: daud ai. Cell. 2019 Apr 18;177(3):556-571.e16. doi: 10.1016/j.cell.2019.02.005. Epub 2019 Apr 4. Cell. 2019. PMID: 30955881 Free PMC article.
PD-1 and PD-L1 antibodies for melanoma.
Tsai KK, Zarzoso I, Daud AI. Tsai KK, et al. Among authors: daud ai. Hum Vaccin Immunother. 2014;10(11):3111-6. doi: 10.4161/21645515.2014.983409. Hum Vaccin Immunother. 2014. PMID: 25625924 Free PMC article. Review.
Layilin augments integrin activation to promote antitumor immunity.
Mahuron KM, Moreau JM, Glasgow JE, Boda DP, Pauli ML, Gouirand V, Panjabi L, Grewal R, Luber JM, Mathur AN, Feldman RM, Shifrut E, Mehta P, Lowe MM, Alvarado MD, Marson A, Singer M, Wells J, Jupp R, Daud AI, Rosenblum MD. Mahuron KM, et al. Among authors: daud ai. J Exp Med. 2020 Sep 7;217(9):e20192080. doi: 10.1084/jem.20192080. J Exp Med. 2020. PMID: 32539073 Free PMC article.
Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma.
Johnson DB, Bordeaux J, Kim JY, Vaupel C, Rimm DL, Ho TH, Joseph RW, Daud AI, Conry RM, Gaughan EM, Hernandez-Aya LF, Dimou A, Funchain P, Smithy J, Witte JS, McKee SB, Ko J, Wrangle JM, Dabbas B, Tangri S, Lameh J, Hall J, Markowitz J, Balko JM, Dakappagari N. Johnson DB, et al. Among authors: daud ai. Clin Cancer Res. 2018 Nov 1;24(21):5250-5260. doi: 10.1158/1078-0432.CCR-18-0309. Epub 2018 Jul 18. Clin Cancer Res. 2018. PMID: 30021908 Free PMC article.
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
Daud AI, Wolchok JD, Robert C, Hwu WJ, Weber JS, Ribas A, Hodi FS, Joshua AM, Kefford R, Hersey P, Joseph R, Gangadhar TC, Dronca R, Patnaik A, Zarour H, Roach C, Toland G, Lunceford JK, Li XN, Emancipator K, Dolled-Filhart M, Kang SP, Ebbinghaus S, Hamid O. Daud AI, et al. J Clin Oncol. 2016 Dec;34(34):4102-4109. doi: 10.1200/JCO.2016.67.2477. Epub 2016 Oct 31. J Clin Oncol. 2016. PMID: 27863197 Free PMC article. Clinical Trial.
Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma.
Algazi AP, Twitty CG, Tsai KK, Le M, Pierce R, Browning E, Hermiz R, Canton DA, Bannavong D, Oglesby A, Francisco M, Fong L, Pittet MJ, Arlauckas SP, Garris C, Levine LP, Bifulco C, Ballesteros-Merino C, Bhatia S, Gargosky S, Andtbacka RHI, Fox BA, Rosenblum MD, Daud AI. Algazi AP, et al. Among authors: daud ai. Clin Cancer Res. 2020 Jun 15;26(12):2827-2837. doi: 10.1158/1078-0432.CCR-19-2217. Epub 2020 May 6. Clin Cancer Res. 2020. PMID: 32376655
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial.
Algazi AP, Othus M, Daud AI, Lo RS, Mehnert JM, Truong TG, Conry R, Kendra K, Doolittle GC, Clark JI, Messino MJ, Moore DF Jr, Lao C, Faller BA, Govindarajan R, Harker-Murray A, Dreisbach L, Moon J, Grossmann KF, Ribas A. Algazi AP, et al. Among authors: daud ai. Nat Med. 2020 Oct;26(10):1564-1568. doi: 10.1038/s41591-020-1060-8. Epub 2020 Oct 5. Nat Med. 2020. PMID: 33020646 Free PMC article. Clinical Trial.
80 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page